Anti-TNF vs ustekinumab after azathioprine failure

for luminal Crohn's after thiopurine failure, both anti-TNF agents and ustekinumab are recognized effective escalation options, and the retrieved evidence does not establish head-to-head superiority of one over the other in this specific sequence ^1–3. one narrative review cites a French cohort suggesting ustekinumab had higher clinical remission and treatment persistence than vedolizumab in anti-TNF–refractory CD, but that comparison is post-anti-TNF, not post-azathioprine, and does not pit ustekinumab against anti-TNF ². ^2–4

What is known:

• Ustekinumab and vedolizumab are effective for induction and maintenance in CD, whether biologic-naïve or anti-TNF–exposed. ^2,3
• Up to 40% of patients lose response to anti-TNF, necessitating escalation to a different mechanism such as ustekinumab or vedolizumab. ³
• In a perianal-CD cohort, among patients failing a first anti-TNF, switching to another anti-TNF was associated with lower colectomy and permanent-diversion rates than switching to ustekinumab, while ustekinumab was associated with higher fistula closure. ⁴

What is unknown / caveats:

• Perianal-CD data favor another anti-TNF over ustekinumab for avoiding colectomy/diversion, yet ustekinumab shows higher fistula closure in the same cohort ⁴
• No retrieved study directly compares anti-TNF vs ustekinumab specifically in azathioprine-failed Crohn's colitis
• The comparative signals come from perianal CD and anti-TNF–refractory populations, not the azathioprine-failure decision point
• This corpus is Crohn's-surgery focused and may under-represent the primary medical-therapy trial literature
• The evidence does not isolate a colonic-CD, post-azathioprine head-to-head between anti-TNF and ustekinumab.

References

1. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. PMID: 31562236.

2. Vegh Z, Kurti Z, Golovics PA, Lakatos PL. Can we Predict Disease Course with Clinical Factors?. Curr Drug Targets. 2018;19(7):791-797. PMID: 28378692.

3. Olbjørn C, Rove JB, Jahnsen J. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Paediatr Drugs. 2020;22(4):409-416. PMID: 32378002.

4. Gubatan J, Frost S, Levitte S, Keyashian K. Rates and Predictors of Long-term Clinical Outcomes in Patients With Perianal Crohn's Disease on Biologic Therapy. J Clin Gastroenterol. 2023;57(6):617-623. PMID: 35703262.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.